That's a great point lorbas. So, within the Prima
Post# of 148190
Do the four measurements provide more statistical strength? Or does the relatively small size create a situation where the p value could be high without a dramatic improvement from the leronlimab group?
And, further if we do in fact achieve p< .05 I would imagine its at the discretion of FDA whether to request a PH3. And would this be determined by the strength of the p value?